Sanofi and Regeneron’s Libtayo is two for two in the last two days—with European officials, that is. One day after the European Commission cleared the PD-1 drug …
The WINTHER trial, NCT01856296, led by investigators from Vall d’Hebron Institute of Oncology – VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave Roussy …
Activase (alteplase) is currently the only FDA-approved drug available for the treatment of acute ischemic stroke (AIS) in the 8MM*; however, novel drugs designed to …
Following a study published in The Lancet Oncology regarding a brand new type of cancer drug that has shown promise in multiple cancer types in …
Despite the ophthalmology market experiencing several research and development (R&D) setbacks during 2018, the launch of three new drugs highlights that the market still offers …
Servier, an independent international pharmaceutical company, and the company Galapagos NV announce the start of a global Phase 2 trial with S201086/GLPG1972 in knee osteoarthritis …
Berlin, Germany, 2 October 2018 – New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove …
C201 phase 2 will study immuno-enhancer antibody GM102, targeting AMHRII as a single agent and in combination with Trifluridine/Tipiracil (Lonsurf®) Paris and Toulouse, France, September …
Brown fat tissue in the body can burn enormous amounts of energy to generate heat, and studies in humans and animals have suggested that increasing …
The researchers at Blum Lab will be using the MILabs’ ultra-high resolution CT to detect novel gold labeled probes in cancerous tissue as well as …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
